

Update on BBS

6. November 2023 BBS Assembly

Hans Ulrich Burger, BBS president

Agenda

BBS
Basel Biometric Society

- 1. Report of the president Hans Ulrich Burger
- 2. Report of the treasurer Fred Sorenson
- 3. Elections
- a) President: Lilla Di Scala, J&J
- b) Treasurer: Fred Sorenson, Xcenda (re-election)
- b) Board members:

Andreas Ziegler, MedizinCampus Davos

Dominic Magirr, Novartis

Hans Ulrich Burger, Roche

4. Closure of the meeting



Report of the president Uli Burger

Activities



Seminars:

March 15: BES seminar on Real world data quality

April 12: Safety estimand seminar

April 19-21: Joint seminar with ADMTP WG

July 21: Seminar on open source software development

Oct 4-5: Car-T seminar

Oct 16: Seminar on estimands in early development

Nov 6: Annual meeting: federated learning and new data types

Trainings:

Feb 10: Statistical engineering

June 21: NextGen meeting

Dec 6: Next Gen training

Activities



In addition 2023:

• Sep 3-7: CEN 2023

Sep 13-14: EFSPI regulatory statistics workshop

Meetings moved to 2024

Jan-Feb 24: Seminar on data sharing

Jan-Feb 24: Speaking statistics training

1Q24: Course on causal inference (with Kelly Van Lancker)

Longer term:

• 2025: ISCB

• 2028: IBC?

Activities



- BBS board is large and active enough to support all these meetings. More challenging is admin support, especially for face to face meetings
- Meetings usually for free
- Meetings usually well attended (today between 50 to many hundreds)
- Meetings most of the time in hybrid format
 - Hybrid format allows people outside Basel to join
 - Hybrid format allows to manage resources (admin support)
 - Hybrid format increases clearly global impact
- There is a move towards more trainings
- More coordination, especially for training, on European level planned (EFSPI)

Next Generation initiative



- Started 2022 to engage stronger with the younger generation and to learn about their needs
 - What are the needs of the next generation?
 - What can we (older ones) do to help them growing?
- One first meeting in 2022 was very successful with follow up meeting this year
- We have now a strong core group of younger colleagues together who work really independent
- We now think to extend the group beyond BBS to a European level under EFSPI. Lets see…
- For BBS we added now one NextGen rep to the BBS board

Succession planning

BBS Basel Biometric Society

Current situation:

- Uli Burger, president
- Fred Sorenson, treasurer
- 17 board members plus one rep from NextGen
- Uli Burger and Marisa Bacchi as EFSPI council members

Future needs:

- To continue having an open culture in the BBS, especially at the board
- We need to put work on many shoulders that we can carry it
- I like the engagement of people at the board and outside. This is crucial for future success!

After 8 years as president it is getting time for me to step back. I am more than happy that Lilla Di Scala volunteers to take it on Importantly, Fred and other board members are willing to continue

Current BBS board

Achim Guettner, Novartis

Brian Hennessy, J&J

Dominik Heinzmann, Roche

Fred Sorenson, Xcendar

Giusi Moffa, University Basel

Juliane Stephanie Schaefer, Roche

Kaspar Rufibach, Roche

Lilla Di Scala, J&J

Marc Vandemeulebroecke, Novartis

Marcel Wolbers, Roche

Marco Cattaneo, University Hospital Basel

Marisa Bacchi, J&J

Olympia Papachristofi, Novartis

Pierre Verweij, Idorsia

Roland Marion-Gallois, BMS

Tracy Glass, University Basel

Antonella Mazzei, NextGen rep, BMS



Questions?



Report of the treasurer Fred Sorenson

Report of the Treasurer 2022 - 2023 Balance from 1. May 2022: CHF 6'091.60

Major Expenses	Main Incoming Revenues	Date (Month)	Amount
Adaptive design training		October 2022	(450.00)
	R-Course	February 2023	3'179.07
EFSPI membership dues 2023		April 2023	(1,253.78)
ADMTP Workshop		April 2023	(43.99)
Bank fees			(3.00)

Current Balance 1. November 2023: CHF 7'519.90



Questions?



Elections

President

Lilla Di Scala, J&J



Treasurer – Re-election



Fred Sorenson, Xcendar

Additional board members



Andreas Ziegler, Medizin Campus Davos

Dominic Magirr, Novartis

Hans Ulrich Burger, Roche



Questions and final discussion